Can GLP‑1 drugs reduce addiction?
Large observational studies find consistent links with lower substance harms
Multiple recent studies — including a very large analysis of U.S. military veterans — have reported that people prescribed GLP‑1 receptor agonists and related anti‑obesity/diabetes drugs had lower rates of new substance‑use diagnoses and reduced likelihood of overdose compared with similar patients who did not receive these medications. The veteran study included roughly 600,000 individuals and found associations across a range of substance classes, while other cohort and case‑control analyses have shown similar signals for alcohol, nicotine and opioid use.
Scientists and clinicians see several plausible explanations for the pattern. GLP‑1 receptors are present in brain regions that regulate reward, motivation and feeding; activation of these pathways by the drugs can blunt responses to drugs of abuse in animal models, and that neurobiological effect could translate into reduced craving or intake in people. Improved metabolic and mental‑health status after weight‑loss or diabetes control may also reduce risky substance use for some patients.
Important caveats remain:
- the existing evidence is observational and cannot prove causation; confounding (for example, differences in healthcare access, diagnosis intensity, or concurrent therapies) could contribute to the associations
- follow‑up times and patient populations vary, so the magnitude and durability of any protective effect are uncertain
- safety, optimal dosing, and whether the benefits apply to people with established substance‑use disorders require randomized trials
If causal, the findings could broaden how these drugs are considered in clinical practice and spur targeted trials to test them as treatments or preventives for substance use. For now, the results are promising but provisional: carefully controlled studies are needed to confirm whether the drugs themselves reduce addiction risk and to define when and for whom they might be useful.